KR20250029954A - 피리도[4,3-d]피리미딘 화합물 - Google Patents
피리도[4,3-d]피리미딘 화합물 Download PDFInfo
- Publication number
- KR20250029954A KR20250029954A KR1020257003513A KR20257003513A KR20250029954A KR 20250029954 A KR20250029954 A KR 20250029954A KR 1020257003513 A KR1020257003513 A KR 1020257003513A KR 20257003513 A KR20257003513 A KR 20257003513A KR 20250029954 A KR20250029954 A KR 20250029954A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- mmol
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263358324P | 2022-07-05 | 2022-07-05 | |
| US63/358,324 | 2022-07-05 | ||
| US202263394338P | 2022-08-02 | 2022-08-02 | |
| US63/394,338 | 2022-08-02 | ||
| US202263414939P | 2022-10-11 | 2022-10-11 | |
| US63/414,939 | 2022-10-11 | ||
| US202363502931P | 2023-05-18 | 2023-05-18 | |
| US63/502,931 | 2023-05-18 | ||
| PCT/IB2023/056844 WO2024009191A1 (en) | 2022-07-05 | 2023-06-30 | Pyrido[4,3-d]pyrimidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250029954A true KR20250029954A (ko) | 2025-03-05 |
Family
ID=87426656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257003513A Pending KR20250029954A (ko) | 2022-07-05 | 2023-06-30 | 피리도[4,3-d]피리미딘 화합물 |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP4551296A1 (enExample) |
| JP (1) | JP2025525406A (enExample) |
| KR (1) | KR20250029954A (enExample) |
| CN (1) | CN119585286A (enExample) |
| AU (1) | AU2023302139A1 (enExample) |
| CA (1) | CA3261000A1 (enExample) |
| CL (1) | CL2024003699A1 (enExample) |
| CO (1) | CO2024016875A2 (enExample) |
| CR (1) | CR20240556A (enExample) |
| DO (1) | DOP2024000275A (enExample) |
| IL (1) | IL317957A (enExample) |
| MA (1) | MA71388A (enExample) |
| MX (1) | MX2024015001A (enExample) |
| PE (1) | PE20250259A1 (enExample) |
| TW (2) | TW202513571A (enExample) |
| WO (1) | WO2024009191A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11697657B2 (en) | 2019-10-28 | 2023-07-11 | Merck Sharp & Dohme Llc | Small molecule inhibitors of KRAS G12C mutant |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| EP4436571A4 (en) * | 2021-11-24 | 2025-10-15 | Merck Sharp & Dohme Llc | SMALL MOLECULE INHIBITORS OF KRAS MUTATIONAL PROTEINS |
| KR20240163107A (ko) | 2022-03-11 | 2024-11-18 | 컴쿼트 바이오사이언시즈 인크. | 헤테로환 화합물 및 이의 용도 |
| IL318647A (en) | 2022-08-05 | 2025-03-01 | Kumquat Biosciences Inc | Heterocyclic compounds and their uses |
| CN120282969A (zh) * | 2022-11-17 | 2025-07-08 | 江苏恒瑞医药股份有限公司 | 稠合三环类化合物、其制备方法及其在医药上的应用 |
| KR20250151412A (ko) | 2023-01-26 | 2025-10-21 | 아비나스 오퍼레이션스, 인코포레이티드 | 세레블론계 kras 분해 단백질 및 이와 관련된 용도 |
| WO2024178304A1 (en) * | 2023-02-24 | 2024-08-29 | Alterome Therapeutics, Inc. | Kras modulators |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| KR20250165440A (ko) | 2023-04-05 | 2025-11-25 | 화이자 인코포레이티드 | 피리도[4,3-d]피리미딘 화합물 |
| WO2024218686A1 (en) * | 2023-04-20 | 2024-10-24 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| TW202509040A (zh) * | 2023-05-16 | 2025-03-01 | 大陸商和記黃埔醫藥（上海）有限公司 | 三環類化合物及其用途 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| US12466840B2 (en) | 2023-10-20 | 2025-11-11 | Merck Sharp & Dohme Llc | Small molecule inhibitors of KRAS proteins |
| WO2025130912A1 (zh) * | 2023-12-19 | 2025-06-26 | 正大天晴药业集团股份有限公司 | 三并环类化合物及其医药用途 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| CN119874616B (zh) * | 2025-03-28 | 2025-05-30 | 四川美域高生物医药科技有限公司 | 一种有机中间体及其制备方法和应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| SG186656A1 (en) | 2007-12-14 | 2013-01-30 | Bristol Myers Squibb Co | Binding molecules to the human ox40 receptor |
| SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
| BR112014007203A2 (pt) | 2011-09-27 | 2017-06-13 | F.Hoffmann-La Roche Ag | composto, composição farmacêutica, método de tratamento, utilização de um composto, conjunto e invenção |
| EP2780039B9 (en) | 2011-11-17 | 2018-04-18 | Pfizer Inc | Cytotoxic peptides and antibody drug conjugates thereof |
| US9884921B2 (en) | 2014-07-01 | 2018-02-06 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| MX2017013297A (es) | 2015-04-13 | 2018-06-19 | Pfizer | Anticuerpos terapeuticos y sus usos. |
| SI3440076T1 (sl) | 2016-04-07 | 2022-09-30 | Glaxosmithkline Intellectual Property Development Limited | Heterociklični amidi uporabni kot proteinski modulatorji |
| BR112018070602A2 (pt) | 2016-04-07 | 2019-02-05 | Glaxosmithkline Ip Dev Ltd | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio |
| CN110191662A (zh) | 2016-11-16 | 2019-08-30 | 温克机器人技术公司 | 用于美容院的机器 |
| US20200109153A1 (en) * | 2017-05-11 | 2020-04-09 | Astrazeneca Ab | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| CN111148762A (zh) | 2017-05-31 | 2020-05-12 | 斯特库伯株式会社 | 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途 |
| TWI757499B (zh) | 2017-06-02 | 2022-03-11 | 美商輝瑞大藥廠 | 對flt3具特異性之抗體及其用途 |
| MA49772A (fr) | 2017-08-04 | 2021-04-21 | Merck Sharp & Dohme | Agonistes benzo[b]thiophène de sting pour le traitement du cancer |
| EP3964516A4 (en) * | 2019-04-28 | 2023-01-11 | Genfleet Therapeutics (Shanghai) Inc. | OXAAZAQUINAZOLINE-7(8H)-KETONE COMPOUND, METHOD FOR PREPARATION AND PHARMACEUTICAL APPLICATION |
| JP7622043B2 (ja) | 2019-08-29 | 2025-01-27 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｄ阻害剤 |
| CN113980032B (zh) * | 2020-07-27 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 稠合四环类衍生物、其制备方法及其在医药上的应用 |
| IL303446A (en) * | 2020-12-15 | 2023-08-01 | Mirati Therapeutics Inc | Azaquinazoline compounds as PAN-KRas inhibitors |
| WO2022199587A1 (zh) * | 2021-03-24 | 2022-09-29 | 南京明德新药研发有限公司 | 嘧啶并杂环类化合物及其应用 |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| CN118019746A (zh) * | 2021-09-27 | 2024-05-10 | 北京加科思新药研发有限公司 | 多环稠环衍生物及其用途 |
-
2023
- 2023-06-30 CR CR20240556A patent/CR20240556A/es unknown
- 2023-06-30 KR KR1020257003513A patent/KR20250029954A/ko active Pending
- 2023-06-30 CN CN202380051793.7A patent/CN119585286A/zh active Pending
- 2023-06-30 CA CA3261000A patent/CA3261000A1/en active Pending
- 2023-06-30 WO PCT/IB2023/056844 patent/WO2024009191A1/en not_active Ceased
- 2023-06-30 MA MA71388A patent/MA71388A/fr unknown
- 2023-06-30 AU AU2023302139A patent/AU2023302139A1/en active Pending
- 2023-06-30 JP JP2024576355A patent/JP2025525406A/ja active Pending
- 2023-06-30 PE PE2024002870A patent/PE20250259A1/es unknown
- 2023-06-30 EP EP23744558.0A patent/EP4551296A1/en active Pending
- 2023-06-30 IL IL317957A patent/IL317957A/en unknown
- 2023-07-04 TW TW113147938A patent/TW202513571A/zh unknown
- 2023-07-04 TW TW112124839A patent/TWI869913B/zh active
-
2024
- 2024-12-02 CL CL2024003699A patent/CL2024003699A1/es unknown
- 2024-12-03 MX MX2024015001A patent/MX2024015001A/es unknown
- 2024-12-09 CO CONC2024/0016875A patent/CO2024016875A2/es unknown
- 2024-12-30 DO DO2024000275A patent/DOP2024000275A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA71388A (fr) | 2025-04-30 |
| CL2024003699A1 (es) | 2025-04-11 |
| CO2024016875A2 (es) | 2024-12-19 |
| PE20250259A1 (es) | 2025-01-29 |
| WO2024009191A1 (en) | 2024-01-11 |
| CN119585286A (zh) | 2025-03-07 |
| CR20240556A (es) | 2025-01-29 |
| AU2023302139A1 (en) | 2024-12-19 |
| MX2024015001A (es) | 2025-01-09 |
| IL317957A (en) | 2025-02-01 |
| EP4551296A1 (en) | 2025-05-14 |
| CA3261000A1 (en) | 2024-01-11 |
| TWI869913B (zh) | 2025-01-11 |
| DOP2024000275A (es) | 2025-01-31 |
| TW202513571A (zh) | 2025-04-01 |
| JP2025525406A (ja) | 2025-08-05 |
| TW202409047A (zh) | 2024-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20250029954A (ko) | 피리도[4,3-d]피리미딘 화합물 | |
| AU2020200407B2 (en) | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof | |
| US12281127B2 (en) | Pyrido[4,3-d]pyrimidine compounds | |
| JP7137733B2 (ja) | ｔｏｌｌ様受容体アゴニストとしてのイミダゾ［４，５－Ｃ］ピリジン誘導体 | |
| WO2024218686A1 (en) | Pyrido[4,3-d]pyrimidine compounds | |
| JP2025114615A (ja) | 治療薬としての細胞毒素のペプチドコンジュゲート | |
| WO2024213979A1 (en) | Pyrido[4,3-d]pyrimidine compounds | |
| WO2024105563A1 (en) | Substituted bicyclic pyridone derivatives | |
| WO2024003773A1 (en) | 2,7-naphthyridine compounds as mastl inhibitors | |
| KR20250100539A (ko) | 피리도[4,3-d]피리미딘 화합물 | |
| JP2025100453A (ja) | ピリド［４，３－ｄ］ピリミジン化合物 | |
| US20240140947A1 (en) | Compound for the treatment of cancer | |
| RU2785124C1 (ru) | Производные имидазо[4,5-с]пиридина в качестве агонистов toll-подобного рецептора | |
| WO2025094035A1 (en) | Toll-like receptor agonists and conjugates thereof | |
| HK40072488A (en) | Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20250204 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application |